- Alpha Cognition (ACOG) has extended the closing date of its overnight marketed offering to October 1, 2021
- Alpha Cognition Inc. is a clinical-stage, biopharmaceutical company dedicated to developing treatments for Alzheimer’s Dementia and ALS
- ALPHA-1062, a new acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, has demonstrated safety and improved tolerability in human clinical trials
- Alpha Cognition Inc. (ACOG) opened trading at C$1.40 per share
Alpha Cognition (ACOG) has extended the closing date of its overnight marketed offering to October 1, 2021.
The previously announced offering is being led by Raymond James Ltd. and includes iA Private Wealth Inc.
Closing of the offering is subject to the receipt of all necessary approvals including final approval of the TSXV.
Alpha Cognition Inc. is a clinical-stage, biopharmaceutical company dedicated to developing treatments for underserved neurodegenerative diseases including Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).
ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease.
ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia and in a nasal spray formulation to treat traumatic brain injury.
Alpha Cognition Inc. (ACOG) opened trading at C$1.40 per share.
